More in this section:

Media Notice: All media representatives and photographers must be escorted by a member of our Media Relations team while on campus. Please contact Kim Savage [kim-savage@smh.com] to arrange onsite interviews or video/photo shoots of patients, staff and healthcare providers in our facilities. For non-media inquiries, please call (941) 917-7777.

New GYN Cancer Specialist Joins FPG Team

New GYN Cancer Specialist Joins FPG Team

Sarasota Memorial recently welcomed a new gynecologic oncologist to its First Physicians Group’s network of medical specialists. Beverly Long, MD, is now treating patients at the FPG Gynecologic Oncology Practice (1888 Hillview St., Sarasota).

Friday, December 18, 2020
SMH 1st in Region to Earn TAVR Certification from ACC

SMH 1st in Region to Earn TAVR Certification from ACC

The American College of Cardiology (ACC) has recognized Sarasota Memorial and its Structural Heart Team for expertise in TAVR (transcatheter valve replacement procedures ). According to the ACC, Sarasota Memorial is the first hospital in Southwest Florida to be awarded Transcatheter Valve Certification.

Thursday, December 17, 2020
SMH Continues Straight-A Streak in Fall 2020 Hospital Safety Report Card

SMH Continues Straight-A Streak in Fall 2020 Hospital Safety Report Card

Sarasota Memorial Hospital again earned an A for patient safety in The Leapfrog Group's Fall 2020 hospital report cards report.

Monday, December 14, 2020
SMH Welcomes 2 New Family Medicine Specialists to Physicians Network

SMH Welcomes 2 New Family Medicine Specialists to Physicians Network

Sarasota Memorial Health Care System is welcoming 2 new family practice physicians to its First Physicians Group (FPG) network and the Suncoast community this month: Jessica Perez-Cardwell, MD, and Rebecca Workman, DO.

Wednesday, December 9, 2020
Monoclonal Antibody Therapy for High Risk COVID-19 Outpatients

Monoclonal Antibody Therapy for High Risk COVID-19 Outpatients

Sarasota Memorial is among a number of hospitals that have been allocated a limited supply of monoclonal antibody therapy for non-hospitalized patients who have been diagnosed with a mild-to-moderate case of COVID-19 and have a high risk for severe disease or hospitalization. SMH has received a limited supply of the Eli Lilly drug (bamlanivimab) and expects to receive shipments of Regeneron’s experimental antibody treatment (a combination of casirivimab and imdevimab), in the coming weeks/months, as supplies are available.

Thursday, December 3, 2020
RSS
First2345791011Last